CNS Pharmaceuticals, Inc. (CNSP)
| Market Cap | 7.50M +89.9% |
| Revenue (ttm) | n/a |
| Net Income | -16.49M |
| EPS | -29.67 |
| Shares Out | 1.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,365 |
| Open | 4.98 |
| Previous Close | 5.38 |
| Day's Range | 4.98 - 5.13 |
| 52-Week Range | 1.90 - 10.59 |
| Beta | 0.98 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of g... [Read more]
Financial Performance
Financial StatementsNews
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
Access the segment here HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innov...
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipel...
CNS Pharmaceuticals files to sell 9.79M shares of common stock for holders
16:57 EDT CNS Pharmaceuticals (CNSP) files to sell 9.79M shares of common stock for holders
CNS Pharmaceuticals Registration statement: Registration filing
CNS Pharmaceuticals filed a registration statement on May 19, 2026, providing details about a securities offering with the SEC.
CNS Pharmaceuticals reports Q1 EPS ($7.30) vs. ($18.93) last year
“We believe CNS Pharmaceuticals (CNSP) has entered a transformational new phase defined by strategic clarity, financial strength and disciplined execution,” said Rami Levin, President and Chief Execut...
CNS Pharmaceuticals sees cash runway ‘beyond’ twelve months
Cash and cash equivalents were $2,951,000 as of March 31, 2026. The cash balance on March 31, 2026 does not account for the gross proceeds from the $22.5 million private…
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with i...
CNS Pharmaceuticals Quarterly report: Q1 2026
CNS Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 14, 2026.
CNS Pharmaceuticals Earnings release: Q1 2026
CNS Pharmaceuticals released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
3 Penny Stocks to Watch Now, 5/5/26
CNS Pharmaceuticals ($CNSP), Elong Power Holding ($ELPW), and Skycorp Solar Group ($PN) are the three penny stocks to watch on May 5, according to TipRanks’ Penny Stock Screener tool. Penny…
Why Is CNS Pharmaceuticals Stock (CNSP) Up Today?
CNS Pharmaceuticals stock underwent a massive rally alongside a $22.5 million private placement.
CNS Pharmaceuticals prices 650,000 shares at $2.30 in private placement
CNS Pharmaceuticals (CNSP) entered into securities purchase agreements for a private placement financing that is expected to result in gross proceeds of approximately $22.5M to the Company, before pla...
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners Proceeds expected to e...
CNS Pharmaceuticals Slides: Investor presentation
CNS Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 22, 2026.
CNS Pharmaceuticals Annual report: Q4 2025
CNS Pharmaceuticals has published its Q4 2025 annual report on March 31, 2026.
CNS Pharmaceuticals launches new corporate growth strategy
CNS Pharmaceuticals (CNSP) has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The strategy is being led by the newly formed executive…
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing markets Strategic trans...
CNS Pharmaceuticals appoints Lynne Kelley as CMO
CNS Pharmaceuticals (CNSP) announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Prior to joining CNS Pharmaceuticals, Dr. Kelley served as CMO at multiple public and private…
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS Newly formed executive team is committed to execution and co...
CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO
CNS Pharmaceuticals (CNSP) announced the Company’s recently appointed President and CEO, Rami Levin, in close alignment with the Board of Directors, has recruited key members to his new executive team...
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation
New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCES...
CNS Pharmaceuticals says priority ‘is to transform’ how company operates
CNS Pharmaceuticals (CNSP) issued a Letter to Shareholders from its newly appointed President and CEO Rami Levin, which read in part, “I am honored to write to you for the…
CNS Pharmaceuticals Issues Letter to Shareholders
Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS Pharmaceuticals Strategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-T...
CNS Pharmaceuticals Inc trading resumes
09:44 EST CNS Pharmaceuticals (CNSP) Inc trading resumes
CNS Pharmaceuticals Inc trading halted, volatility trading pause
09:32 EST CNS Pharmaceuticals (CNSP) Inc trading halted, volatility trading pause